Reports 11 Nov 2020 Navigating the Immunotherapy Maze Today, the global immunotherapy drugs market is valued at €139B ($163B) and is estimated to reach a staggering value of €149.3B ($174.6B) by 2025. Without a doubt, it is a flourishing field with new research emerging as you read. Discover now how antibodies, T cells, and exosomes are changing the immunotherapy field! While antibodies have […] November 11, 2020 - 2 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
In Depth 9 Nov 2020 Gene Drives: A Controversial Tool to Fight Malaria The advent of CRISPR gene editing has enabled the creation of gene drives, a technology that can increase the odds of a certain gene being inherited. While the technology could help us tackle malaria and control invasive species, the scientific community is divided on whether it is ethical. The possibility of creating gene drives was […] November 9, 2020 - 12 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
In Depth 4 Nov 2020 The Return of Gene Therapy Gene therapy is a hot area in the biotech industry right now, with many treatments in development and a number of recent approvals. However, the path has not always been a smooth one. Gene therapy has been one of the biggest success stories of the 21st century. Genetic diseases were once seen as incurable, etched […] November 4, 2020 - 8 minutesmins - By Farhan Mitha Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2020 Kiadis’ Natural Killer Cell Therapies Earn €308M Acquisition by Sanofi The French big pharma Sanofi has offered €308M to acquire the Dutch firm Kiadis Pharma and get hold of cancer cell therapies based on a type of immune cells called natural killer cells. The offer comes not long after Sanofi inked a deal worth up to €857.5M to license a preclinical-stage cancer cell therapy from […] November 3, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 2 Nov 2020 Synthetic Biology: The Next Step in the Cannabinoid Revolution The recent relaxation of cannabis legislation in Canada, many parts of the US, and several European countries has attracted a lot of investment. While most endeavors focus on extracting cannabinoid compounds from cannabis plants, there’s a growing interest in producing them using engineered microbes. Nehtaji Gallage was first acquainted with cannabinoids when she was a […] November 2, 2020 - 6 minutesmins - By Kostas Vavitsas Share WhatsApp Twitter Linkedin Email
News and Trends 30 Oct 2020 Bayer’s AskBio Acquisition Strong Statement For Gene Therapy in Europe This week, German big pharma Bayer announced a €3.5B takeover of Asklepios BioPharmaceutical, a well known US gene therapy specialist. This is only one of many examples of the funding windfall experienced by the gene therapy field in 2020. Despite the difficulties posed by the Covid-19 pandemic, 2020 has been a good year for gene […] October 30, 2020 - 6 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 29 Oct 2020 Universal Flu Vaccines Yield Second Clinical Failure This Year In a blow to hopes for better protection from seasonal flu, last week’s phase III failure of BiondVax’s universal flu vaccine follows the phase II flop of Vaccitech’s flu vaccine in January. Last week proved a major setback for the Israeli biotech BiondVax. The company’s vaccine — designed to protect against multiple strains of flu […] October 29, 2020 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 28 Oct 2020 Do Natural Killer Cells Hold the Key to Treating Blood Cancers? Novel immunotherapies, like T cell therapy, may have shown recent successes but they also come with a number of setbacks, such as long timelines and serious adverse reactions. As CEO of the Dutch biotech Kiadis Pharma, Arthur Lahr has been leading the development of a technology that could overcome these limitations by using natural killer […] October 28, 2020 - 7 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
Expert Advice 26 Oct 2020 How to Prepare for a Successful Biotech IPO Any biotech company that has reached a certain size and is in need of investment will have to consider the critical question: is it time to go public? Navigating the stock market can be particularly challenging for biotech companies. The biotech industry has some unique requirements that sets it apart from, say, tech or real […] October 26, 2020 - 10 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Oct 2020 Top 10 Companies Combining AI and Drug Discovery in Europe Rapid advances in artificial intelligence over the last decade have the potential to revolutionize how drugs are developed. These are the top 10 companies in Europe that are working to make AI drug discovery a reality. Drug development is a slow and increasingly expensive process. Artificial intelligence (AI) has the potential to make the drug […] October 19, 2020 - 8 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 15 Oct 2020 Swiss Biotech Launches Amidst Hot Streak for Rare Autoimmune Disease Swiss biotech Chord Therapeutics launched this week with a €13.7M Series A, becoming the latest company to tackle the rare condition neuromyelitis optica, for which three therapies have been approved in less than a year. Neuromyelitis optica spectrum disorders, previously also known as Devic disease, affect up to 2 in 100,000 people around the world. […] October 15, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 14 Oct 2020 Spatial Transcriptomics Landscape Shifts With Two Major Acquisitions The Swedish firm Cartana and US-based ReadCoor have recently been snapped up by the US giant 10x Genomics to get hold of their spatial transcriptomics technology. What impact will these acquisitions have on the burgeoning field going forward? Last week, 10x Genomics took over ReadCoor for a smooth €298M ($350M). This followed the acquisition of […] October 14, 2020 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email